Related Experiment Videos
Primary therapy for Cushing's disease with metyrapone
JAMA
|March 7, 1986
Summary
Metyrapone effectively treated a young patient with Cushing's syndrome for four years, resolving symptoms and promoting growth. This study suggests metyrapone can be a sole therapy for Cushing's disease, with a dosing schedule mimicking natural cortisol rhythms.
Area of Science:
- Endocrinology
- Pediatric Endocrinology
Background:
- Cushing's syndrome is a complex endocrine disorder.
- Pituitary-dependent Cushing's syndrome requires effective long-term management.
Observation:
- A 13-year-old boy diagnosed with pituitary-dependent Cushing's syndrome received metyrapone monotherapy.
- Treatment lasted four years with daily dosage of 2.0 g.
Findings:
- All clinical and biochemical signs of Cushing's disease resolved within months.
- The patient experienced significant growth (23.0 cm) and regained normal health.
- Metyrapone was well-tolerated with no significant side effects.
- A specific dosing schedule (2 PM and 8 PM) helped normalize diurnal cortisol variation.
Implications:
- Metyrapone monotherapy is a viable treatment option for Cushing's disease.
- Optimized dosing can improve therapeutic outcomes and patient well-being.
- This case highlights the potential of metyrapone in pediatric Cushing's syndrome management.